PharmaEssentia (藥華藥) achieved a major commercial milestone as its flagship drug, Ropeg (Ropeginterferon alfa-2b), was officially included in the latest NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Essential Thrombocythemia (ET).

• Top-Tier Recommendation: Ropeg was designated as a Category 1 "Preferred Regimen" for high-risk ET patients who are hydroxyurea-intolerant or resistant. Category 1 indicates high-level clinical evidence and uniform expert consensus.
• Clinical Data: The inclusion was driven by the SURPASS-ET Phase III trial, where Ropeg showed a 42.9% durable clinical response rate compared to just 6.0% for the Anagrelide control group ($p=0.0001$).
• Market Outlook: CEO Dr. Ko-Chung Lin noted that NCCN recognition often accelerates insurance coverage decisions. While already the "Preferred" treatment for Polycythemia Vera (PV), Ropeg’s ET application is currently under FDA review, with a PDUFA goal date of August 30, 2026.

Resource: 獲NCCN列Category 1首選 藥華藥Ropeg再添利多